From: Current challenges in different approaches to control COVID-19: a comprehensive review
Name of the vaccine | Developer | Developer country | Vaccine type | No. of doses | Efficacy (%) | Storage (°C) | References |
---|---|---|---|---|---|---|---|
BNT162b2 (Comirnaty) | Pfizer-BioNtech | USA and Germany | mRNA | IM (2) | 95 | − 80 to – 60 | Polack et al. (2020) |
mRNA-1273 (Moderna COVID-19 Vaccine) | Moderna | USA | mRNA | IM (2) | 94.0 | − 25 to − 15 | Baden et al. (2021) |
Ad26.COV2.S (Janssen COVID-19 vaccine) | Janssen Pharmaceuticals | USA and Germany | Viral vector | IM 1 | 81.7 | 2–8 | Sadoff et al. (2021) |
ChAdOx1 nCoV-19 (AZD-1222) (Covishield) | Oxford-AstraZeneca | UK, Sweden and India | Viral vector | IM (2) | 81 | 2–8 | Voysey et al. (2021) |
Sputnik V | Gamaleya Research Institute | Russia | Viral vector | IM (2) | 91.6 | 2–8 | Logunov et al. (2021) |
BBV152 (Covaxin) | Bharat Biotech | India | Inactivated | IM (2) | 78 | 2–8 | Ella et al. (2021) |
CronaVac | Sinovac | China | Inactivated | IM (2) | 50.4 | 2–8 | Zhang et al. (2021) |
BBIBP-CorV | Sinopharm | China | Inactivated | IM (2) | 79.3 | 2–8 | Xia et al. (2021) |
NVX-CoV2373 | Novavax | USA | Protein subunit | IM (2) | 96 | 2–8 | Shinde et al. (2021) |
CVnCoV | CureVac | Germany | mRNA | IM (2) | 48.2 | 2–8 | Hadj Hassine (2021) |
AD5-nCOV (Convidecia) | CanSino Biologics | China | Viral vector | IM, IN (1) | 63 | 2–8 | Wu et al. (2021) |
SCB-2019 | Clover Biopharmaceu ticals | China | Protein subunit | IM | 67 | 2–8 | Bravo et al. (2022) |
ZyCoV-D | Cadila Healthcare | India | DNA plasmid | ID (3) | 66.6 | 2–8 | Chavda et al. (2021) |
ZF2001 (Zifivax) | Anhui Zhifei Longcom | China | Protein subunit | IM (3) | 82 | 2–8 | Yang et al. (2021) |